Abstract
Preclinical evaluation of novel anti-smallpox vaccines and antiviral treatments often rely on mouse challenge models using pathogenic vaccinia virus, such as Western Reserve (WR) strain or other orthopoxviruses. Traditionally, efficacy of treatment is evaluated using various readouts, such as lethality (rare), measurements of body weight loss, pox lesion scoring, and determination of viral loads in internal organs by enumerating plaques in sensitive cell lines. These methodologies provide valuable information about the contribution of the treatment to protection from infection, yet all have similar limitations: they do not evaluate dissemination of the virus within the same animal and require large numbers of animals. These two problems prompted us to turn to a recently developed whole body imaging technology, where replication of recombinant vaccinia virus expressing luciferase enzyme (WRvFire) is sensed by detecting light emitted by the enzyme in the presence of d-luciferin substrate administered to infected animal. Bioluminescence signals from infected organs in live animals are registered by the charge-coupled device camera in IVIS instrument developed by Caliper, and are converted into numerical values. This chapter describes whole body bioimaging methodology used to determine viral loads in normal live BALB/c mice infected with recombinant WRvFire vaccinia virus. Using Dryvax vaccination as a model, we show how bioluminescence data can be used to determine efficacy of treatment. In addition, we illustrate how bioluminescence and survival outcome can be combined in Receiver Operating Characteristic curve analysis to develop predictive models of lethality that can be applied for testing of new therapeutics and second-generation vaccines.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S (1987) Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 7:725–737
Ow DW, Wet DE Jr, Helinski DR, Howell SH, Wood KV, Deluca M (1986) Transient and stable expression of the firefly luciferase gene in plant cells and transgenic plants. Science 234:856–859
Gould SJ, Subramani S (1988) Firefly luciferase as a tool in molecular and cell biology. Anal Biochem 175:5–13
Rodriguez JF, Rodriguez D, Rodriguez JR, McGowan EB, Esteban M (1988) Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc Natl Acad Sci USA 85:1667–1671
Lin MZ, McKeown MR, Ng HL, Aguilera TA, Shaner NC, Campbell RE, Adams SR, Gross LA, Ma W, Alber T, Tsien RY (2009) Autofluorescent proteins with excitation in the optical window for intravital imaging in mammals. Chem Biol 16:1169–1179
Luker KE, Luker GD (2008) Applications of bioluminescence imaging to antiviral research and therapy: multiple luciferase enzymes and quantitation. Antivir Res 78:179–187
Zaitseva M, Kapnick SM, Scott J, King LR, Manischewitz J, Sirota L, Kodihalli S, Golding H (2009) Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. J Virol 83:10437–10447
Luker KE, Luker GD (2010) Bioluminescence imaging of reporter mice for studies of infection and inflammation. Antivir Res 86:93–100
Pichler A, Prior JL, Piwnica-Worms D (2004) Imaging reversal of multidrug resistance in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl Acad Sci USA 101:1702–1707
Townsley AC, Weisberg AS, Wagenaar TR, Moss B (2006) Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol 80:8899–8908
Gross EA, Swenberg JA, Fields S, Popp JA (1982) Comparative morphometry of the nasal cavity in rats and mice. J Anat 135:83–88
Acknowledgments
We express our gratitude to John Scott for help in generating data for this study. This project was funded in part with Federal funds from the National Institute of Health, Department of Health and Human Services, under IAA 224-06-1322.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Zaitseva, M., Kapnick, S., Golding, H. (2012). Measurements of Vaccinia Virus Dissemination Using Whole Body Imaging: Approaches for Predicting of Lethality in Challenge Models and Testing of Vaccines and Antiviral Treatments. In: Isaacs, S. (eds) Vaccinia Virus and Poxvirology. Methods in Molecular Biology, vol 890. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-876-4_10
Download citation
DOI: https://doi.org/10.1007/978-1-61779-876-4_10
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-875-7
Online ISBN: 978-1-61779-876-4
eBook Packages: Springer Protocols